Protein-based therapeutics such as monoclonal antibodies are widely developed and used by the biopharmaceutical industry; in 2023, mAb-based therapeutics represented over half of the Top Ten best-selling drugs of the year, globally, and are one of the fastest growing modalities. However, these large molecules pose unique challenges in relation to sample preparation and analytical characterisation, making robust and fit-for-purpose methods essential to achieve high quality results.